Association of the MscI polymorphism of the dopamine D3 receptor gene with tardive dyskinesia in schizophrenia

Vincenzo S. Basile; Mario Masellis; Farideh Badri; Andrew D. Paterson; Herbert Y. Meltzer; Jeffrey A. Lieberman; Steven G. Potkin; Fabio Macciardi; James L. Kennedy

doi:10.1016/S0893-133X(98)00114-6

Association of the MscI polymorphism of the dopamine D3 receptor gene with tardive dyskinesia in schizophrenia

Vincenzo S. Basile, Mario Masellis, Farideh Badri, Andrew D. Paterson, Herbert Y. Meltzer, Jeffrey A. Lieberman, Steven G. Potkin, Fabio Macciardi, James L. Kennedy^*

^*Corresponding author for this work

Psychiatry and Behavioral Sciences

Research output: Contribution to journal › Article › peer-review

155 Scopus citations

Abstract

In 112 schizophrenic patients previously treated with typical neuroleptics, we investigated the putative role of the dopamine D3 receptor gene (DRD3) in tardive dyskinesia (TD). Patients were assessed for TD severity using the Abnormal Involuntary Movement Scale (AIMS) and were subsequently genotyped for the MscI polymorphism that identifies a serine to glycine substitution in DRD3. A modified analysis of covariance model, which incorporated several clinical risk factors for TD, was utilized to detect differences in TD severity among the various genotypic groups. The glycine allele of DRD3 was found to be associated with typical neuroleptic-induced TD (F[2,95] = 8.25, p < .0005). Higher mean AIMS scores were found in patients homozygous for the glycine variant of the DRD3 gene, as compared to both heterozygous and serine homozygous patients. Although replication is necessary, this finding supports a role for the dopamine D3 receptor in the pathogenesis of TD. Copyright (C) 1999 American College of Neuropsychopharmacology.

Original language	English (US)
Pages (from-to)	17-27
Number of pages	11
Journal	Neuropsychopharmacology
Volume	21
Issue number	1
DOIs	https://doi.org/10.1016/S0893-133X(98)00114-6
State	Published - Jul 1999

Keywords

DRD3
Dopamine
Extrapyramidal side effects
Genetic association
Neuroleptics
Pharmacogenetics
Receptor binding
Risk factor
Tardive dyskinesia

ASJC Scopus subject areas

Pharmacology
Psychiatry and Mental health

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/S0893-133X(98)00114-6

Cite this

@article{eb609d3c1935452d89b062bfc67f10d9,

title = "Association of the MscI polymorphism of the dopamine D3 receptor gene with tardive dyskinesia in schizophrenia",

abstract = "In 112 schizophrenic patients previously treated with typical neuroleptics, we investigated the putative role of the dopamine D3 receptor gene (DRD3) in tardive dyskinesia (TD). Patients were assessed for TD severity using the Abnormal Involuntary Movement Scale (AIMS) and were subsequently genotyped for the MscI polymorphism that identifies a serine to glycine substitution in DRD3. A modified analysis of covariance model, which incorporated several clinical risk factors for TD, was utilized to detect differences in TD severity among the various genotypic groups. The glycine allele of DRD3 was found to be associated with typical neuroleptic-induced TD (F[2,95] = 8.25, p < .0005). Higher mean AIMS scores were found in patients homozygous for the glycine variant of the DRD3 gene, as compared to both heterozygous and serine homozygous patients. Although replication is necessary, this finding supports a role for the dopamine D3 receptor in the pathogenesis of TD. Copyright (C) 1999 American College of Neuropsychopharmacology.",

keywords = "DRD3, Dopamine, Extrapyramidal side effects, Genetic association, Neuroleptics, Pharmacogenetics, Receptor binding, Risk factor, Tardive dyskinesia",

author = "Basile, {Vincenzo S.} and Mario Masellis and Farideh Badri and Paterson, {Andrew D.} and Meltzer, {Herbert Y.} and Lieberman, {Jeffrey A.} and Potkin, {Steven G.} and Fabio Macciardi and Kennedy, {James L.}",

note = "Funding Information: JLK is the recipient of a NARSAD Independent Investigator award. This work was supported by the Medical Research Council of Canada and the Ontario Mental Health Foundation.",

year = "1999",

month = jul,

doi = "10.1016/S0893-133X(98)00114-6",

language = "English (US)",

volume = "21",

pages = "17--27",

journal = "Neuropsychopharmacology",

issn = "0893-133X",

publisher = "Nature Publishing Group",

number = "1",

}

TY - JOUR

T1 - Association of the MscI polymorphism of the dopamine D3 receptor gene with tardive dyskinesia in schizophrenia

AU - Basile, Vincenzo S.

AU - Masellis, Mario

AU - Badri, Farideh

AU - Paterson, Andrew D.

AU - Meltzer, Herbert Y.

AU - Lieberman, Jeffrey A.

AU - Potkin, Steven G.

AU - Macciardi, Fabio

AU - Kennedy, James L.

N1 - Funding Information: JLK is the recipient of a NARSAD Independent Investigator award. This work was supported by the Medical Research Council of Canada and the Ontario Mental Health Foundation.

PY - 1999/7

Y1 - 1999/7

N2 - In 112 schizophrenic patients previously treated with typical neuroleptics, we investigated the putative role of the dopamine D3 receptor gene (DRD3) in tardive dyskinesia (TD). Patients were assessed for TD severity using the Abnormal Involuntary Movement Scale (AIMS) and were subsequently genotyped for the MscI polymorphism that identifies a serine to glycine substitution in DRD3. A modified analysis of covariance model, which incorporated several clinical risk factors for TD, was utilized to detect differences in TD severity among the various genotypic groups. The glycine allele of DRD3 was found to be associated with typical neuroleptic-induced TD (F[2,95] = 8.25, p < .0005). Higher mean AIMS scores were found in patients homozygous for the glycine variant of the DRD3 gene, as compared to both heterozygous and serine homozygous patients. Although replication is necessary, this finding supports a role for the dopamine D3 receptor in the pathogenesis of TD. Copyright (C) 1999 American College of Neuropsychopharmacology.

AB - In 112 schizophrenic patients previously treated with typical neuroleptics, we investigated the putative role of the dopamine D3 receptor gene (DRD3) in tardive dyskinesia (TD). Patients were assessed for TD severity using the Abnormal Involuntary Movement Scale (AIMS) and were subsequently genotyped for the MscI polymorphism that identifies a serine to glycine substitution in DRD3. A modified analysis of covariance model, which incorporated several clinical risk factors for TD, was utilized to detect differences in TD severity among the various genotypic groups. The glycine allele of DRD3 was found to be associated with typical neuroleptic-induced TD (F[2,95] = 8.25, p < .0005). Higher mean AIMS scores were found in patients homozygous for the glycine variant of the DRD3 gene, as compared to both heterozygous and serine homozygous patients. Although replication is necessary, this finding supports a role for the dopamine D3 receptor in the pathogenesis of TD. Copyright (C) 1999 American College of Neuropsychopharmacology.

KW - DRD3

KW - Dopamine

KW - Extrapyramidal side effects

KW - Genetic association

KW - Neuroleptics

KW - Pharmacogenetics

KW - Receptor binding

KW - Risk factor

KW - Tardive dyskinesia

UR - http://www.scopus.com/inward/record.url?scp=0032982269&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032982269&partnerID=8YFLogxK

U2 - 10.1016/S0893-133X(98)00114-6

DO - 10.1016/S0893-133X(98)00114-6

M3 - Article

C2 - 10379516

AN - SCOPUS:0032982269

SN - 0893-133X

VL - 21

SP - 17

EP - 27

JO - Neuropsychopharmacology

JF - Neuropsychopharmacology

IS - 1

ER -

Association of the MscI polymorphism of the dopamine D3 receptor gene with tardive dyskinesia in schizophrenia

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this